Regulatory Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars Big Molecule WatchOn May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.Read full story pharminent June 4, 2026 (Last updated: June 5, 2026) Big Molecule Watch On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: SCOTUS backs generic firm Hikma in skinny label disputeNext: Pfizer signs licence agreement with Chai for AI drug discovery Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
